Search clinical trials for: DE-127 Ophthalmic Solution high dose

Total 254 results

Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)

Myopia

Singapore
Santen Inc.

Completed

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SEE-1)

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Santen Inc.

Completed

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Santen Pharmaceutical Co., Ltd.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Japan
Santen Inc.

Completed

DE-117 Spectrum 5 Study

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Mitotech, SA
ORA, Inc.

Completed

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Keratoconjunctivitis Sicca

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen Inc.

Completed

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma or Ocular Hypertension

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

Primary Open Angle Glaucoma or Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Open Angle Glaucoma or Ocular Hypertension

Singapore
Avizorex Pharma, S.L.

Unknown

Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome (AVX012CT001)

Dry Eye Syndrome

Spain
Senju Pharmaceutical Co., Ltd.

Completed

Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

Corneal Epithelial Disorders

United States
Santen Pharmaceutical Co., Ltd.

Completed

To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

Dry Eye Disease

Taiwan
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Open Angle Glaucoma or Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Allergic Conjunctivitis

Japan
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
ONL Therapeutics

Active, not recruiting

A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients With Progressing Open Angle Glaucoma

Open Angle Glaucoma

Australia, New Zealand
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

Canada
Sylentis, S.A.

Completed

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Dry Eye Disease | Sjögren Syndrome

United States, Spain
Sylentis, S.A.

Completed

Safety Study of Tivanisiran to Treat Dry Eye (FYDES)

Dry Eye Disease

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

Open Angle Glaucoma or Ocular Hypertension

Japan
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Neurotrophic Keratitis

United States, Canada
Glaukos Corporation

Recruiting

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

United States
Santen Inc.

Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (ANGEL-2)

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Santen Pharmaceutical Co., Ltd.

Completed

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Glaucoma and Ocular Hypertension

United States
Fovea Pharmaceuticals SA

Completed

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

Diabetic Macular Edema

United States, Australia, Belgium, Czech Republic, France, Germany, Israel, Italy, Poland, Spain
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Santen Inc.

Completed

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -

Healthy Male Adults

Japan
Santen Pharmaceutical Co., Ltd.

Completed

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Ocular Hypertension | Open Angle Glaucoma

Japan
Aerie Pharmaceuticals

Completed

Rocklatan® Evaluation

Glaucoma

United States
Gian Sagar Medical College and Hospital

Withdrawn

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Vitiligo | Repigmentation
Marinomed Biotech AG

Completed

Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis

Allergic Rhinitis | Allergic Conjunctivitis

Austria
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Santen SAS

Active, not recruiting

A Phase III Multinational Multicenter Investigator-Masked Randomised Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Surface Disease | Open-Angle Glaucoma or Ocular Hypertension

France
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
Allena Pharmaceuticals

Completed

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

Nephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria | Dietary Hyperoxaluria

United States
Vicus Therapeutics

Completed

Regimen for the Treatment of Cachexia in Subjects With NSCLC (VT-122)

Cachexia

India, United States

3

Subscribe